Understand the NDC transition to a 12-digit format. Learn how the FDA NDC change impacts systems, serialization, and pharma supply chain operations.
On March 5, 2026, the FDA published a final rule that marks the beginning of a major NDC transition. This change represents the most significant restructuring of the National Drug Code (NDC) system in decades.
The shift from a 10-digit NDC to a universal 12-digit NDC format is not a minor update. It is a fundamental transformation of how NDC data is structured, managed, and exchanged across the U.S. pharmaceutical supply chain.
Every system, transaction, and trading partner relying on NDC will be affected by this transition.
For years, the industry has managed a “Tetris-like” environment of fragmented NDC configurations (4-4-2, 5-3-2, and 5-4-1), while converting them into 11-digit formats for HIPAA billing. The NDC transition ends this complexity by introducing a single, standardized NDC structure.
One format to rule them all: The 12-Digit NDC Standard (6-4-2)
At the core of the NDC transition is the introduction of a single, universal 12-digit NDC format: 6-4-2.
This new NDC structure includes:
• 6-digit labeler code
• 4-digit product code
• 2-digit package code
The transition to a unified NDC format eliminates the need for multiple NDC representations across regulatory and billing systems. Historically, inconsistent NDC formats have been a major source of data integrity issues.
As Nubinno Technical Consultant Sebastian Coronado notes:
“Multiple formats = persistent confusion, conversion errors, and inefficiencies across the industry.”
By standardizing the NDC format, the FDA is removing conversion logic and significantly reducing operational friction across the pharmaceutical supply chain.
NDC transition and labeler code expansion: a 900-year supply
A key driver of the NDC transition is the exhaustion of existing NDC labeler codes.
By expanding the labeler code from 5 to 6 digits, the FDA is adding approximately 900,000 new NDC codes. This ensures long-term scalability of the NDC system.
This part of the NDC transition is considered a future-proofing strategy, creating what is estimated to be a “900-year supply” of labeler codes. It allows the NDC system to support market growth and onboarding of new pharmaceutical companies without risk of code depletion.
The hidden risk in NDC transition: “silent failures” in systems
One of the most critical risks in the NDC transition is not visible at first glance.
Many systems handling NDC data–such as ERP, WMS, and serialization platforms–were designed with fixed assumptions about NDC length and structure.
During the NDC transition, these assumptions can lead to silent failures, where systems process incorrect NDC data without generating alerts.
Key risks include:
• incorrect parsing of 12-digit NDC
• truncation of expanded labeler codes
• misalignment of NDC segments
• propagation of corrupted NDC data across systems
“If your system expects NDC instead of handling it – you have a problem.”
To successfully navigate the NDC transition, organizations must audit all systems where NDC logic is embedded, especially within Master Data Management (MDM) and integrations.
Having a dedicated team responsible for the NDC transition is critical to identify and manage these risks early.
NDC Transition complexity peak: The dual data phase (2033–2036)
The most complex stage of the NDC transition will occur between 2033 and 2036.
During this period, both 10-digit and 12-digit NDC formats will coexist. This phase, often referred to as the Dual Data Phase, introduces significant risk for data consistency and serialization.
Key NDC transition risks during this phase:
• GTIN Mapping errors
The NDC is a core element of the GTIN. Changes in NDC structure directly impact GTIN generation and validation.
- Broken EPCIS event chains
Inconsistent NDC formats across partners may disrupt EPCIS traceability under DSCSA requirements. - Duplicate product records
Systems may treat different NDC formats for the same product as separate entries.
Managing this stage of the NDC transition requires strict data governance and synchronization across all systems and partners.
Preparing early–even though the timeline may seem distant–will significantly reduce the risk during this complex transition phase.
Why the NDC transition is GxP-critical (not just an IT update)
The NDC transition is often underestimated as a technical update. In reality, it is a GxP-critical transformation.
Because the NDC is part of the Product Identifier required under DSCSA, any changes to NDC handling must be validated.
This includes:
• updating specifications (URS, FS) for NDC handling
• regression testing of all systems using NDC
• validation of serialization platforms
• updating packaging lines and barcode structures
Failure to properly validate NDC-related changes can result in compliance risks and operational disruptions.
NDC Transition timeline: key FDA milestones
The FDA has defined a clear timeline for the NDC transition:
• March 5, 2026 – Final Rule published (start of NDC transition)
• March 7, 2033 – FDA begins assigning 12-digit NDCs
• 2033–2036 – Dual Data Phase (coexistence of NDC formats)
• Post-March 2036 – Enforcement actions for non-compliance
Organizations must align their NDC transition strategies with this timeline to avoid disruptions.
The real challenge of the NDC transition: synchronization
The NDC transition is not just a system upgrade–it is a synchronization challenge.
This change impacts every layer of the pharmaceutical ecosystem:
• physical product labeling
• digital serialization data (EPCIS)
• financial and billing processes
• master data governance
The success of the NDC transition depends on synchronization across systems, data, and trading partners.
Speaking with partners early is essential to ensure they are aware of the changes and ready to handle the new NDC format.
If no one owns the NDC-to-GTIN mapping today, who will own it during the transition?
